Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 1, 2007, Pages 26-34

  Benítez, Sónia ^a   Pérez, Antonio ^a   Sánchez Quesada, José Luis ^a   Wagner, Ana María ^a   Rigla, Mercedes ^a   Arcelus, Rosa ^a   Jorba, Óscar ^a   Ordóñez Llanos, Jordi ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Electronegative low density lipoprotein; Inflammation; Type 2 diabetes mellitus

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIOXIDANT; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; FATTY ACID; FRUCTOSAMINE; GLUCOSE; INSULIN; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ADULT; AGED; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN GLYCOSYLATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BLOOD GLUCOSE; CELLS, CULTURED; CHEMISTRY, PHYSICAL; CHEMOKINE CCL2; CHROMATOGRAPHY, ION EXCHANGE; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERLEUKIN-8; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RECEPTORS, LDL;

EID: 33846509268     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.643     Document Type: Article

References (47)

1. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes 1992; 41: 68-73.
2. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
3. Scheffer PG, Henry RMA, Wever EJM, et al. LDL oxidative modifications in well- or moderately controlled type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 298-304.
4. Kim HJ, Kurup IV. Nonenzymatic glycosylation of human low density lipoprotein; evidence for in vivo and in vitro glycosylation. Metabolism 1982; 31: 348-352.
5. Sánchez-Quesada JL, Pérez A, Caixàs A, et al. Electronegative low-density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 1996; 39: 1469-1476.
6. Moro E, Zambón C, Pianetti S, et al. Electronegative low density lipoprotein subform is increased in type 2 (non-insulin-dependent) microalbuminuric patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 1998; 35: 161-164.
7. Moro E, Alessandrini P, Zambón C, et al. Is glycation of low density lipoproteins in patients with type 2 diabetes mellitus a LDL pre-oxidative condition?. Diabet Med 1999; 16: 663-669.
8. Sánchez-Quesada JL, Pérez A, Caixàs A, et al. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab 2001; 86: 3243-3249.
9. Sánchez-Quesada JL, Otal-Entraigas C, Franco M, et al. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with familial hypercholesterolemia. Am J Cardiol 1999; 84: 655-659.
10. Benítez S, Ordóñez-Llanos J, Franco M, et al. Effect of simvastatin in familial hypercholesterolemia on the affinity of charge-differing low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am J Cardiol 2004; 93: 414-420.
11. Vedic B, Jeunemaitre X, Mégnien JL, et al. Charge heterogeneity of LDL in asymptomatic hypercholesterolemic men is related to lipid parameters and variations in the apoB and CIII genes. Arterioscler Thromb Vasc Biol 1998; 18: 1780-1789.
12. Sánchez-Quesada JL, Benítez S, Franco M, et al. Density distribution of electronegative LDL (LDL(-)) in normolipemic and hyperlipemic subjects. J Lipid Res 2002; 43: 699-705.
13. Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol 2004; 15: 329-335.
14. Sevanian A, Hwang J, Hodis H, et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16: 784-793.
15. Hodis HN, Kramsch DM, Avogaro P, et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein (electronegative LDL). J Lipid Res 1994; 35: 669-677.
16. Demuth K, Myara I, Chappey B, et al. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 1996; 16: 773-783.
17. Chen CH, Jiang T, Yang JH, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003; 107: 2102-2108.
18. de Castellarnau C, Sánchez-Quesada JL, Benítez S, et al. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 2281-2287.
19. Sánchez-Quesada JL, Camacho M, Antón R, et al. Electronegative LDL of FH subjects. Chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 2003; 166: 261-270.
20. Ziouzenkova O, Asatryan L, Sahady D, et al. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 2003; 278: 39874-39881.
21. Avogaro P, Bittolo-Bon G, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8: 79-87.
22. Sevanian A, Bittolo-Bon G, Cazzolato G, et al. Electronegative LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res 1997; 38: 419-428.
23. Sánchez-Quesada JL, Benítez S, Pérez A, et al. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. Diabetologia. 2005; 48: 2162-2169.
24. Sánchez-Quesada JL, Ortega H, Payés-Romero A, et al. LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. Atherosclerosis 1997; 132: 207-213.
25. Fukunaga K, Suzuki T, Takama K. Highly sensitive high-performance liquid chromatography for the measurement of malondialdehyde in biological samples. J Chromatogr 1993; 621: 77-81.
26. Khoo J, Miller E, McLaughlin P, et al. Enhanced macrophage uptake of low-density lipoprotein after self-aggregation. Arteriosclerosis 1988; 8: 348-358.
27. Benítez S, Sánchez-Quesada JL, Ribas V, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative LDL subfraction. Circulation 2003; 108: 92-96.
28. Benítez S, Villegas V, Bancells C, et al. Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to non-esterified fatty acids and lysophosphatidylcholine content. Biochemistry 2004; 43: 15863-15872.
29. Stephan ZF, Yurachek EC. Rapid fluorimetric assay of LDL receptor activity by DiI labelled LDL. J Lipid Res 1993; 34: 325-330.
30. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes?. Diabet Med 1991; 8: 411-419.
31. Zhang B, Kaneshi T, Ohta T, Saku K. Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J Lipid Res 2005; 46: 2265-2277.
32. Gambino R, Uberti B, Alemanno N, Pisu E, Pagano G, Cassader M. In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control. Atherosclerosis 2004; 173: 103-107.
33. Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-134.
34. Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization and metabolism of the glycated and non-glycated subfractions of low-density lipoproteins isolated from type 1 diabetic patients and nondiabetic subjects. Diabetes 1995; 44: 1093-1098.
35. Nigon F, Lesnik P, Pouis M, Chapman MJ. Discrete subspecies of human low density lipoprotein are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32: 1741-1753.
36. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 471-474.
37. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004; 14: 161-165.
38. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8 and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-1199.
39. Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133: 81-91.
40. Zozulinska D, Majchrzak A, Sobieska M, et al. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 1999; 42: 117-118.
41. Benítez S, Camacho M, Arcelus R, et al. Increased lysophosphatidyleholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Atherosclerosis 2004; 177: 299-305.
42. Tomasik A, Jache W, Skrzep-Poloczek B, et al. Circulating electronegatively charged low-density lipoprotein in patients with angiographically documented coronary artery disease. Scand J Clin Lab Med 2003; 63: 259-266.
43. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272: 17895-17898.
44. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
45. Winkler K, Abletshauser C, Friedrich I, et al. Fluvastatin slow-release lowers platelet-activating factor acetylhydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 1153-1159.
46. Serban M, Tanaseanu C, Kosaka T, et al. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin dependent (type 2) diabetes mellitus. J Cell Mol Med 2002; 6: 643-647.
47. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543-559.